 At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10 owners really only buy shares of a company for one reason they believe the stock price will rise and they want to profit. The following are a few of significant insider purchases reported last week, all small-cap biotechs. 